Dun says it's "the world's first and only diffuse midline glioma-specific drug screening robot", and hopes it will amplify the rate at which they can develop new treatments.
"And I hope, in the short term, we'll come up with strategies to increase the survival of patients and give families hope that at least there is a treatment.
Over the past five years, the research team had identified chemicals that could get into the brain and target the disease, using tumours they have growing in the lab.
"But the problem is testing them is really slow, really laborious, and we wanted to take out any kind of bias in the system by getting it to become automated," he said.
"This robot which we call the JEM-bot, will allow us to screen multiple combinations at any given time, in the growth pattern of a diffuse midline glioma cell so that it can inform our studies."
He said it's heartbreaking to receive a brain cancer diagnosis, let alone to be told there's no treatment.
"And for the most part because there isn't any recognised treatment the best thing is often just to do nothing, and that's a really hard thing for any parent and kid to swallow.
"Thanks to Jemima's amazing legacy we are able to test combinations of drugs based on the biology of DIPG that we're developing in real time."
A total of $696,420 was donated to Dun through Jemima's fundraising efforts, including $5382 of her own life savings.
She also donated her own brain tumour to Dun's research, and it will be the first to be tested with the JEM-bot.